Skip to main content
Media Hub

Press Releases

For all press and media enquiries please contact mediarelations@chiesi.com 

  • Corporate

    Chiesi Group appoints Paolo Paoletti to its Board of Directors

    HIGHLIGHTS: Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today. An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership. His…

  • Corporate

    Chiesi appoints David Khougazian as Group Chief Executive Officer to lead the next phase of innovation-driven growth

    Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins…

  • Corporate

    Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities

    HIGHLIGHTS H1 2026 revenues of €1.89 billion, up + 3.6% at CER versus H1 2025, driven by growth in the inhaled triple therapy portfolio and strong momentum in the rare diseases therapeutic area Continued investment in innovation with €426 million invested in R&D (22.5% of sales) Completed strategic…

  • Corporate

    Chiesi completes the KalVista acquisition

    Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group…

  • Corporate

    Chiesi Group Announces New Chair and Vice Chair

    Highlights: Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generations Maria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an…

  • Corporate

    Chiesi to acquire KalVista Pharmaceuticals

    Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s…

  • Corporate

    Chiesi's FY2025 results and a leadership transition

    Highlights: Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs.…

  • Corporate

    Chiesi selects Salesforce Agentforce Life Sciences

    International biopharmaceutical leader accelerates digital transformation with AI-powered customer engagement, unified data, and next-generation integration capabilities APRIL 20, 2026 – Chiesi Group, an international biopharmaceutical group, has selected Salesforce’s Agentforce Life Sciences for…

  • Corporate

    Chiesi and Bespak partner on UK inhaler production

    Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers [1], ensuring patients retain continuity of care while reducing carbon emissions Bespak’s leadership in…